Results 101 to 110 of about 80,159 (268)

Selenomethionine Regulates the Arachidonic Acid Metabolism‐Ferroptosis‐Inflammation Axis to Ameliorate Colitis

open access: yesAnimal Research and One Health, EarlyView.
Selenomethionine can ameliorate arachidonic acid‐induced colonic injury through synergistic mechanisms, including alleviating inflammatory responses, improving barrier integrity, enhancing antioxidant capacity by upregulating selenoprotein expression, selectively regulating AA metabolism to reduce pro‐inflammatory oxylipins and promote the production ...
Huihui Tian   +8 more
wiley   +1 more source

Kidney Hematopoietic Stem and Progenitor Cells Contribute to Myeloid Development and Pathology in Lupus Nephritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective The hematopoietic system maintains homeostasis by balancing myeloid and lymphoid cell production in the bone marrow (BM). In response to increased hematopoietic demand, extramedullary hematopoiesis (EMH) may occur in nonlymphoid organs. We investigated the role of EMH and kidney‐resident hematopoietic stem and progenitor cells (HSPCs) in ...
Hansol Yi   +9 more
wiley   +1 more source

Autoreactivity Versus Autoimmunity: Characteristics of Autoantigen‐Specific CD4 T Cells in Rheumatoid Arthritis and Health

open access: yesArthritis &Rheumatology, EarlyView.
Objective CD4 T cells specific for citrullinated (cit) peptides are key players in rheumatoid arthritis (RA) immunopathogenesis. Characterizing these cells and identifying features of healthy and RA‐associated autoreactivity will provide valuable insight into disease mechanisms and form the basis of immune state biomarkers to facilitate the next ...
James A. Stanway   +13 more
wiley   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia   +16 more
wiley   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

open access: yesArthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz   +13 more
wiley   +1 more source

Complement Activation Linked to Type II Interferon Signaling in Still Disease

open access: yesArthritis &Rheumatology, EarlyView.
Objective Still disease (SD) is an autoinflammatory syndrome characterized by innate immune dysregulation. Although complement can drive inflammation, its involvement in SD remains to be defined. Thus, we aimed to assess complement activation in SD. Methods Complement was assessed using transcriptomic, proteomic, and in vitro approaches. RNA sequencing
Freya M. C. H. Huijsmans   +115 more
wiley   +1 more source

Early synovial regulatory T cell engagement in posttraumatic osteoarthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Posttraumatic osteoarthritis (PTOA) develops despite restoration of joint biomechanics, suggesting that early post‐injury biological processes within the synovium shape disease trajectories. We investigated whether synovial regulatory T (Treg) cells are engaged during the early phase following joint injury and whether experimental enrichment ...
Xueyou Zhang   +5 more
wiley   +1 more source

Human Monocytic Models Reveal Genotype‐Dependent Inflammatory Programs in VEXAS Syndrome

open access: yesArthritis &Rheumatology, EarlyView.
Objective VEXAS syndrome is a severe X‐linked autoinflammatory disorder caused by somatic mutations in ubiquitin‐like modifier activating enzyme 1 (UBA1), with clinical outcomes that vary by UBA1 genotype. We aimed to elucidate genotype‐specific inflammatory programs and identify potential therapeutic targets.
Kana Higashitani   +10 more
wiley   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort   +8 more
wiley   +1 more source

High‐Dimensional Spectral Flow Cytometry Panel for Immunophenotypic Characterization of Fixed Whole Blood Samples

open access: yesCytometry Part A, EarlyView.
ABSTRACT Peripheral blood mononuclear cells (PBMCs) are commonly used for immune profiling in clinical research, but their isolation and cryopreservation present logistical challenges, particularly in settings with limited access to research facilities. To address this, we implemented a whole blood fixation protocol to preserve surface protein epitopes
Vaishnavi Parthasarathy   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy